Turkey Firms Up More Positive Policies As It Seeks Biotech Boost
This article was originally published in PharmAsia News
Having prepared a Biotechnology Strategy Document and Action Plan last year, Turkey now seems to have a roadmap in this sector. The blueprint includes many policies that the research-based pharmaceutical industry has been advocating for at least 10 years, such as promoting biotech investments through legal reforms to strengthen intellectual property rights and boosting transparent and predictable public policies for market access and reimbursement.
You may also be interested in...
Turkey’s efforts to control rising rates of COVID-19 are compromising the ability of hospitals to pay their debts to medtech and pharmaceutical companies. The government has devised a payments plan, but there is catch.
The Turkish medtech industry’s ongoing hospital payments problems appeared likely to come back onto the government’s agenda, with the national economy recovering somewhat in late 2019. But COVID-19 dashed those hopes.
Growth prospects for Turkey’s medical technology market are significant, but local companies have complained about public policies that are harmful to business and about the ongoing crisis in the hospital system. Now, international medtechs are starting to react, with some downscaling local operations and portfolios. Association of Research Based Medical Technologies Manufacturers president Umut Gokalp laid out the problems being faced by industry, and what action he thinks the government should take.